Thulium Laser Vaporization versus Vapoenucleation (without morcellation) Technique for BPH: Do We Have a Winner?
Journal of Endoluminal Endourology · 2019
DOI: 10.22374/jeleu.v2i1.26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endoluminal Endourology, 2019. Verfasst von Debanga Sarma und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Objective The thulium laser surgery is a relatively new approach in which a wavelength of approximately 2 μm is emitted in continuous-wave mode, thus enabling the precise incision of tissue by using a wavelength that matches the water absorption peak of 1.92 μm in tissue. However, no published multinational study or other evidence definitively declares the superiority of thulium vaporization (ThuVAP) over thulium vapoenucle-ation (ThuVEP) without morcellator for better management of bothersome benign prostatic hyperplasia. The present study aims to evaluate the efficacy of vaporization and vapoenucleation (without a morcellator) in thulium laser prostatectomy for the treatment of benign prostatic hyperplasia.
Methods
A retrospective analysis of 82 patients who underwent thulium laser prostatectomy between February 2017 and January 2018 with ThuVAP and ThuVEP techniques was done and outcome measures analyzed were International Prostate Symptom Score (IPSS), quality-of-life score (QoL), maximum flow rate (Q max), post-void residual (PVRU), total operating time, laser time and resected tissue weight.
Results
No significant differences were noted between ThuVAP and ThuVEP in terms of post-operative prostate volume (22.4 vs. 21.7 mL) and post-operative prostate specific antigen (PSA) (2.54 vs. 1.85 ng/mL). Nonetheless, there were differences between the groups in total lasing time (56.5 vs. 44.8 min, p = 0.001) and total operative time (88.5 vs. 71.5 min, p= 0.001). There was also a significant difference in IPSS, QoL score, Q max, and PVRU at 6 weeks, 3 months, 6 months and 9 months after surgery.
Conclusion
ThuVEP provides a superior reduction of prostate volume and better short-term clinical outcomes than ThuVAP in the treatment of patients with benign prostatic hyperplasia. Furthermore, ThuVEP results in significantly lower urethral discomfort rates with significant improvement in IPSS as compared to ThuVAP which is maintained over time. The hospital stay and catheter indwelling time are shorter in the ThuVEP group and the complications associated with it appear to be lower than ThuVAP group.
Zitieren
APA
Sarma, D., Singh, Y., Baruah, S. J., Rajeev, T., Barua, S. K., Bagchi, P. K., Phukan, M., & Kashyap, M. P. (2019). Thulium Laser Vaporization versus Vapoenucleation (without morcellation) Technique for BPH: Do We Have a Winner?. Journal of Endoluminal Endourology. https://doi.org/10.22374/jeleu.v2i1.26
Vancouver
Sarma D, Singh Y, Baruah SJ, Rajeev T, Barua SK, Bagchi PK, et al. Thulium Laser Vaporization versus Vapoenucleation (without morcellation) Technique for BPH: Do We Have a Winner?. Journal of Endoluminal Endourology. 2019. doi:10.22374/jeleu.v2i1.26
BibTeX
@article{Sarma2019,
author = {Sarma, Debanga and Singh, Yashasvi and Baruah, Saumar Jyoti and Rajeev, T.P. and Barua, Sasanka Kumar and Bagchi, Puskal Kumar and Phukan, Mandeep and Kashyap, Manash Pratim},
title = {Thulium Laser Vaporization versus Vapoenucleation (without morcellation) Technique for BPH: Do We Have a Winner?},
journal = {Journal of Endoluminal Endourology},
year = {2019},
doi = {10.22374/jeleu.v2i1.26}
}
EUVIMED